Abstract
Intravenous administration of the beta-adrenergic blocking drug, alprenolol, to a group of patients with severe obstructive disease of the airways caused no deterioration of symptoms and a clinically insignificant fall in FEV1 in the majority. A minor reduction in PaO2 occurred which suggests that alprenolol may cause local hypoventilation and/or pulmonary arteriovenous shunting. The presence of obstructive disease of the airways does not seem to pose an absolute contraindication to the use of alprenolol, although caution must be exercised in its use in such patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
